Ch. Kouroussis

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Molecular Detection of Cytokeratin-19–Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance

Aliki Stathopoulou, Ioannis G. Vlachonikolis, D. Mavroudis et al. · Journal of Clinical Oncology · 2002 · 340 citations

Medicine, Molecular Medicine, Oncology +13

Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer

Nikolaos Xenidis, Ioannis G. Vlachonikolis, D. Mavroudis et al. · Annals of Oncology · 2003 · 103 citations · Full text

Medicine, Oncology, Breast Oncology +10

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

John Souglakos, N. Ziras, Stylianos Kakolyris et al. · British Journal of Cancer · 2012 · 64 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer

G. Stathopoulos, Dimitriοs Mavroudis, Ch. Kouroussis et al. · Annals of Oncology · 2001 · 64 citations

Medicine, Oncology, Pharmacology +15